Izotropic Corporation (IZOZF)
| Market Cap | 17.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.67M |
| Shares Out | n/a |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,000 |
| Average Volume | 37,497 |
| Open | 0.2660 |
| Previous Close | 0.2660 |
| Day's Range | 0.2548 - 0.2660 |
| 52-Week Range | 0.0186 - 0.3316 |
| Beta | 1.22 |
| RSI | 45.89 |
| Earnings Date | Sep 26, 2025 |
About Izotropic
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. The company develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses offering high resolution, true 3D dedicated breast imaging with 360‐degree image acquisition and can be used with or without injectable contrast. Izotropic Corporation was incorporated in 2016 and is headquartered in Surrey, Canada. [Read more]
News
Izotropic Marks Breast Cancer Awareness Month by Highlighting Gaps in Care and the Need for IzoView Breast CT
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“ Izotropic ”, or the “ Company ”), a me...
AI in Breast Imaging: New BreastCT.com Article Examines IzoView's Competitive Edge
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“ Izotropic ”, or the “ Company ”), a m...
Izotropic's IzoView Breast CT the First in Category to Offer Patent-Pending Personalized Radiation Dose
- Patent-pending pre-scan technology enables custom radiation dose tailored to patient's unique breast size and composition - - Feature aligns with personalized medicine trends driving the global brea...
Izotropic Closes Non-Brokered Private Placement and Engages Awareness Consultants
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - September 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical de...
Izotropic Publishes New FAQ Page for Investors, Analysts, and Healthcare Decision-Makers
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“ Izotropic ”, or the “ Company ”), a m...
Izotropic Gains Visibility as AI Market Broadens Beyond Tech
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - September 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical de...
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Robert Thast, CEO of Izotropic Corp.
AUSTIN, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce ...
Izotropic Secures Exclusive Rights to Patented Computer-Aided Diagnosis for Breast CT
- U.S. patent protection covers computer-aided diagnosis (“CADx”) with breast CT - - Izotropic holds the exclusive rights to this patent and breast CT technology under global license agreement - - CAD...
Izotropic's AI Breakthrough Positions IzoView to Redefine Breast CT Imaging Standards
- Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT - - Trained on 15 years of specialized breast CT data and protected as...
Izotropic Announces Non-Brokered Private Placement & Extends Warrants
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 26, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical devic...
BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic's IzoView Device
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“ Izotropic ”, or the “ Company ”), a me...
Izotropic Introduces New Corporate Website & Brand Identity
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical devic...
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“ Izotropic ”, or the “ Company ”), a me...
Izotropic's IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers
- Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand - Company positioned to lead in dense breast imaging,...
Izotropic's IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies
- IzoView positioned to disrupt high-growth breast imaging markets with target device price of USD $500K - IzoView to launch into projected fastest-growing imaging category with potential to displace...
Izotropic Prepares New Platforms to Educate and Engage
- Strategic awareness initiatives underway ahead of IzoView commercialization - - Company podcast and breasct.com website in development to expand engagement - - Market-facing activities aligned with ...
Izotropic Provides Marketing Update
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 13, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device c...
Izotropic Revises License Agreement with The Regents of the University of California
- License agreement enables U.S. FDA approval or foreign equivalent (CE mark) - - Amendment aligns with Company's timelines for IzoView product launch - - Agreement amendment fees of USD $85K payable ...
Izotropic's U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
- Regulatory alignment with FDA confirmed, clearing path to pivotal U.S. clinical trial - - 150-page strategic business plan and advanced financial models completed - - Investor outreach launched to f...
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device c...
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
- FDA meeting facilitated positive collaborative exchange - - Key topics included the clinical study protocol synopsis, the benefits versus risks of contrast-enhancement, and the management of breast ...
Izotropic to Present at Investor Conference March 13th
- CEO to discuss IzoView's competitive advantage, expansion strategy, and potential revenue models - - Event includes live Q and A, attendance is complimentary - - Individual and institutional investo...
FDA Sets Meeting Date with Izotropic
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical devi...
Izotropic Closes Non-Brokered Private Placement
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 14, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical devi...
Izotropic Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 7, 2025) -...